TRIPLE NEGATIVE BREAST NEOPLASMS
Clinical trials for TRIPLE NEGATIVE BREAST NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST NEOPLASMS trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising targeted therapy for tough breast cancer hits roadblock
Disease control TerminatedThis study tested whether adding the drug alpelisib to standard chemotherapy (nab-paclitaxel) could help people with advanced triple negative breast cancer that has specific genetic changes (PIK3CA mutation or PTEN loss). The trial enrolled 137 participants but was stopped early.…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Cancer drug combo shows promise but study halted early
Disease control TerminatedThis study tested a combination of two drugs—pembrolizumab (an immunotherapy) and mifepristone (a hormone blocker)—in people with advanced HER2-negative breast cancer. The goal was to see if the combination could shrink tumors. The study was stopped early after enrolling 24 parti…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New pill targets Hard-to-Treat cancers in early human test
Disease control TerminatedThis early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Promising combo for Triple-Negative breast cancer stalls as trial ends early
Disease control TerminatedThis early-phase trial tested a drug called leronlimab combined with the chemotherapy carboplatin in people with a specific type of advanced triple-negative breast cancer (CCR5-positive). The goal was to find a safe dose and see if it could slow cancer growth. However, the study …
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:01 UTC